JAN 3 1 2003

veral sheets if necessary)

ATTY, DOCKET NO.

APPLN. NO.

4057-32 APPLICANT 09/257,188**RECEIVED**

GLENN et al.

FEB 0 4 2003

E 1 05 40

GROUP

February 25, 1999

1644

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS FILING DATE *EXAMINE Z INITIAL CLASS SUBCLASS IF APPROPRIATE DOCUMENT NUMBER DATE NAME AR 3,964,482 06/1976 Gerstel et al. BR 4,775,361 10/1988 Jacques et al. 5,003,987 04/1991 Grinwald CR Petereit et al. DR 5,133,970 07/1992 ER 5,182,109 C1 10/2001 Tamura et al. FR 5,250,023 10/1993 Lee et al. GR 5,279,544 01/1994 Gross et al. HR 5,688,523 11/1997 Garbe et al. **IR** 5,879,326 03/1999 Godshall et al. JR 5.993.849 11/1999 Assmus et al. KR 5,993,852 11/1999 Foldvari et al. LR 6,019,982 02/2000 Clements et al. MR 6,022,316 02/2000 Eppstein et al. NR 6,033,673 03/2000 Clements OR 6,033,684 03/2000 Norcia PR 6,063,399 05/2000 Assmus et al. QR 6,090,790 07/2000 Eriksson RR 6,142,939 11/2000 Eppstein et al. SR 11/2000 6,149,919 Domenighini et al. TR 6,165,458 12/2000 Foldvari et al. UR 6,165,500 12/2000 Cevc VR 6,190,367 02/2001 Hall ₩R 6,190,689 02/2001 Hoffmann et al. XR 6,207,184 03/2001 Ikeda et al. FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY YES CLASS SUBCLASS YR ZR AAR BBR CCR OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) DDR EER **FFR** GGR HHR IIR *Examiner 11/11/03

INFORMATION DISCLOSURE ATTY, DOCKET NO. APPLN. NO. RECEIVED CITATION 09/257,188 4057-32 APPLICANT FEB 0 4 2003 GLENN et al. (Undersonal sheets if necessary) GROUP FILING DATE **TECH CENTER 1600/2900** 1644 February 25, 1999 U.S. PATENT DOCUMENTS FILING DATE CLASS SUBCLASS IF APPROPRIATE DOCUMENT NUMBER NAME DATE AR 6,256,533 07/2001 Yuzhakov et al. Roser et al. BR 6,290,991 09/2001 CR 6,312,612 11/2001 Sherman et al. DR 6,331,266 12/2001 Powell et al. ER 6,331,310 12/2001 Roser et al. FR 6,334,856 01/2002 Allen et al. GR 6,348,212 02/2002 Hymes et al. HR 6,348,450 02/2002 Tang et al. IR 6,365,178 04/2002 Venkateshwaran et al. JR 6,379,324 04/2002 Gartstein et al. KR 6.406.705 06/2002 Davis et al. LR 6,413,523 07/2002 Clements MR 6,440,096 08/2002 Lastovich et al. NR 09/2002 6,451,240 Sherman et al. OR 6,454,755 09/2002 Godshall PR 6,471,903 10/2002 Sherman et al. FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO QR WO 95/17211 06/1995 WIPO RR WIPO WO 96/06627 03/1996 SR WO 96/19976 04/1996 **WIPO** TR WO 97/04832 02/1997 WIPO UR WO 97/07734 03/1997 WIPO VR WO 98/00193 01/1998 WIPO $\overline{\mathsf{WR}}$ 07/1998 WIPO WO 98/29134 XR WO 99/13915 03/1999 WIPO YR WO 99/26662 WIPO 06/1999 ZR WIPO WO 99/61078 12/1999 OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) AAR BBR CCR DDR EER **FFR** GGR HHR IIR JJR KKR LLR *Examiner 11/11/18

Examiner

APPLN, NO. INFORMATION DISCLOSURE ATTY, DOCKET NO. **CITATION** 4057-32 09/257,188 RECEIVED APPLICANT GLENN et al. FEB 0 4 2003 FILING DATE GROUP se several sheets if necessary) JAN 3 1 2003 1644 February 25, 1999 TECH CENTER 1800/201 U.S. PATENT DOCUMENTS TE TONDE! FILING DATE **EXAMINER** SUBCLASS IF APPROPRIATE DOCUMENT NUMBER DATE NAME INITIAL FOREIGN PATENT DOCUMENTS TRANSLATION YES DOCUMENT DATE COUNTRY CLASS SUBCLASS NO 09/1999 WIPO AR WO 99/47164 BR WO 99/47165 09/1999 **WIPO** WIPO CR WO 99/47167 09/1999 WIPO DR WO 00/33812 06/2000 WIPO FR WO 00/74714 12/2000 WO 00/74763 12/2000 WIPO GR HR WIPO WO 00/74763 A3 12/2000 IR WO 00/74766 12/2000 WIPO WIPO 05/2001 JR WO 01/34185 KR WO 01/90758 11/2001 **WIPO** LR WO 02/02179 01/2002 WIPO MB WO 02/05889 WIPO 01/2002 WIPO NR WO 02/07813 01/2002 OR WO 02/64162 08/2002 WIPO PR WO 02/64193 08/2002 WIPO OR WO 02/74244 **WIPO** 09/2002 OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) BECKER "Dengue fever virus and Japanese encephalitis virus synthetic peptides, with motifs to fit HLA class I haplotypes prevalent in human populations in endemic regions, can be used for application to skin Langerhans cells to prime antiviral CD8 cytotoxic T cells (CTLs) - A novel approach to the protection of humans" Virus Genes 9 (1994) 33-45 BECKER "An analysis of the role of skin Langerhans cells (LC) in the cytoplasmic processing of HIV-1 peptides after "Peplotion" transepidermal transfer and HLA class I presentation to CD8 CTLs - An approach to immunization of humans" Virus Genes 9 (1994)133-147 CASTLE "Clinical relevance of age-related immune dysfunction" Clin Infect Dis 31 (2000) 578-585 CHEN "Adjuvation of epidermal powder immunization" Vaccine 19 (2001) 2908-2917 WR CHEN "Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization" J Virol 75 (2001) 7956-7965 EL-GHORR "Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice" FEMS Immunol Med Micro 29 (2000) 255-261 GLUECK "Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated

influenza vaccine Escherichia coli heat-labile toxin as a mucosal adjuvant" J Infect Dis 181 (2000) 1129-1132 GOCKEL "Transcutaneous immunization induces mucosal and systemic immunity: A potent method for

targeting immunity to the female reproductive tract" Mol Immunol 37 (2000) 537-544

~ . .

INFORMATION DISCLOSURE CITATION			ATTY. DOCKET NO.				A	APPLN. NO.				
			4057	4057-32				09/257,188 FEB 0 4 2003				
			APPLIC					<u> </u>	+EB	042	000	
TPE			GLE	NN et al.				•	TEOU	- (n03	
0	Kook	everal sheets if necessary)		FILING DATE				ROUP	EUH CENT	THE CENTER 1800/000		
JAN 3 1 20	AN 3 1 2020 20			February 25, 1999				TECH CENTER 1600/2900				
k	E			U.S. PATENT	DOCU	MEN	ITS					
SEXANIE		DOCUMENT NUMBER	DATE		NAM	F		CLASS	SUBCLASS		DATE	
	AR		DATE							1 7 11 7 11	<u></u>	
	BR											
	CF											
	DF											
FOREIGN PATENT DOCUMENTS												
										TRANSLATION		
		DOCUMENT	DATE ————		COUNT	TRY_		CLASS	SUBCLASS	YES	NO	
	ER						·····					
	FR			·							<u> </u>	
		OTHER DOCL										
176	GR	HAGIWAR "Effectiven		•				abile entero	toxin (LT H4	4A) as a	an	
/Jap		adjuvant for nasal influ										
//	НК	HAGIWARA "Effects of					,				,	
	B subunits supplemented with a trace amount of the holotoxin on the brain" Vaccine 19 (20) IR HIOE "Comparison of adjuvant formulations of cytotoxic T cell induction using synthetic pep (1996) 412-418											
									mono popuo	- Vao	- O III	
	JR KATOH "Acute cutaneous barrier perturbation induces maturation of Langerhans' cells in hairless r Derm Venereol (Stockh) 77 (1997) 365-369									ess mic	e" Acta	
	KR	KR KUMAMOTO "Induction of tumor-specific protective immunity by <i>in situ</i> Langerhans cell vaccine" Nature Biotech 20 (2002) 64-69										
	I B											
)	LR LIU "Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antige specific immune responses" Vaccine 20 (2002) 42-48									/1-		
	MR	LU "Mutant <i>Escherichi</i>				(R19	92G)] enha	nces protect	ive humoral	and cel	lular	
		immune responses to										
	NR	McCLUSKIE "Route ar										
		human primates" Mol I								·		
	OR	OCKENHOUSE "Sequ										
	DD	erythrocytes identified PODDA "The adjuvant										
1 1		vaccine" Vaccine 19 (2			illi nove	auj	uvanis. Laj	Jenence will	THE WIT JOS	aujuvaie	;u	
	QR	TAKIGAWA "Percutan			ion via c	orne	um barrier	-disrupted m	urine skin fo	r experi	imental	
		tumor immunoprophylaxis" Ann NY Acad Sci 941 (2001) 139-146										
		"Tuberculin, Purified P										
SR WATABE "Protection against influenza virus challenge by topical application of influenza DNA									vaccine) "		
A 2		Vaccine 19 (2001) 443	4-4444				···					
	TR UR	 										
	VR				<u></u>							
	WR											
	XR									-		
*Examine						, ,						
Examme	71	Cuto			11	11	5	1				